2019International Journal of Molecular SciencesOpen access

An Update on Anti-CD137 Antibodies in Immunotherapies for Cancer

Dinh‐Toi Chu, Nguyen Xuan Bac, Khanh Hoang Nguyen, Nguyen Le Bao Tien, Vo Van Thanh, Vu Thi Nga, Võ Trương Như Ngọc, Dương Thị Anh Đào, Lê Ngọc Hoàn, Quoc Viet Hung Nguyen, Nguyễn Thị Trung Thu, Van-Huy Pham, Lê Nguyên Vũ, Thuy Anh Vu Pham, Deepak B. Thimiri Govinda Raj

Open full text 83 citations

Abstract

The selective expression of CD137 on cells of the immune system (e.g., T and DC cells) and oncogenic cells in several types of cancer leads this molecule to be an attractive target to discover cancer immunotherapy. Therefore, specific antibodies against CD137 are being studied and developed aiming to activate and enhance anti-cancer immune responses as well as suppress oncogenic cells. Accumulating evidence suggests that anti-CD137 antibodies can be used separately to prevent tumor in some cases, while in other cases, these antibodies need to be co-administered with other antibodies or drugs/vaccines/regents for a better performance. Thus, in this work, we aim to update and discuss current knowledge about anti-cancer effects of anti-CD137 antibodies as mono- and combined-immunotherapies.

Open-access reader

About this research paper

What this paper is about

The selective expression of CD137 on cells of the immune system (e.g., T and DC cells) and oncogenic cells in several types of cancer leads this molecule to be an attractive target to discover cancer immunotherapy. Therefore, specific antibodies against CD137 are being studied and developed aiming to activate and enhance anti-cancer immune responses as well as suppress oncogenic cells. Accumulating evidence suggests that anti-CD137 antibodies can be used separately to prevent tumor in some cases, while in other cases, these antibodies need to be co-administered with other antibodies or drugs/vaccines/regents for a better performance. Thus, in this work, we aim to update and discuss current knowledge about anti-cancer effects of anti-CD137 antibodies as mono- and combined-immunotherapies.

Why it matters

OpenAlex reports 83 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

The selective expression of CD137 on cells of the immune system (e.g., T and DC cells) and oncogenic cells in several types of cancer leads this molecule to be an attractive target to discover cancer immunotherapy. Therefore, specific antibodies against CD137 are being studied and developed aiming to activate and enhance anti-cancer immune responses as well as suppress oncogenic cells. Accumulating evidence suggests that anti-CD137 antibodies can be used separately to prevent tumor in some cases, while in other cases, these antibodies need to be co-administered with other antibodies or drugs/vaccines/regents for a better performance. Thus, in this work, we aim to update and discuss current knowledge about anti-cancer effects of anti-CD137 antibodies as mono- and combined-immunotherapies.

Key concepts: CD137, Antibody, Cancer immunotherapy, Cancer, Immunotherapy, Immune system, Cancer cell, Cancer research

Related papers

Back to paper searchBrowse research topicsOriginal source
An Update on Anti-CD137 Antibodies in Immunotherapies for Cancer — Research Paper | ScholarLens